Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
4(40%)
Results Posted
75%(3 trials)
Terminated
1(10%)

Phase Distribution

Ph phase_1
4
40%
Ph phase_2
4
40%
Ph phase_3
2
20%

Phase Distribution

4

Early Stage

4

Mid Stage

2

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
4(40.0%)
Phase 2Efficacy & side effects
4(40.0%)
Phase 3Large-scale testing
2(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

4

trials recruiting

Total Trials

10

all time

Status Distribution
Active(5)
Completed(4)
Terminated(1)

Detailed Status

Active, not recruiting4
Completed4
Terminated1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
4
Success Rate
80.0%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (40.0%)
Phase 24 (40.0%)
Phase 32 (20.0%)

Trials by Status

terminated110%
active_not_recruiting440%
completed440%
not_yet_recruiting110%

Recent Activity

4 active trials
Showing 5 of 10
not_yet_recruitingphase_2

Bepirovirsen Liver Biopsy Study

NCT07696520
completedphase_1

Study to Evaluate the Effect of Bepirovirsen on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers

NCT06422767
active_not_recruitingphase_2

Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)

NCT06497504
completedphase_3

Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)

NCT05630820
completedphase_3

Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)

NCT05630807
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT07696520Phase 2

Bepirovirsen Liver Biopsy Study

Not Yet Recruiting
NCT06422767Phase 1

Study to Evaluate the Effect of Bepirovirsen on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers

Completed
NCT06497504Phase 2

Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)

Active Not Recruiting
NCT05630820Phase 3

Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)

Completed
NCT05630807Phase 3

Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)

Completed
NCT06537414Phase 2

A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

Active Not Recruiting
NCT04954859Phase 2

Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)

Active Not Recruiting
NCT05330455Phase 1

Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection

Terminated
NCT07168356Phase 1

A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney Disease

Active Not Recruiting
NCT06058390Phase 1

A Study to Evaluate the Relative Bioavailability of Subcutaneous Bepirovirsen When Delivered From a Vial or Prefilled Syringe Fitted With a Safety Syringe Device in Healthy Adult Participants

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10